

# Keith C Ferdinand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8778724/publications.pdf>

Version: 2024-02-01

128  
papers

10,286  
citations

76326

40  
h-index

33894

99  
g-index

130  
all docs

130  
docs citations

130  
times ranked

11521  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. <i>New England Journal of Medicine</i> , 2004, 351, 2049-2057.	27.0	1,605
2	Resistant Hypertension: Diagnosis, Evaluation, and Treatment. <i>Hypertension</i> , 2008, 51, 1403-1419.	2.7	1,333
3	Resistant Hypertension: Diagnosis, Evaluation, and Treatment. <i>Circulation</i> , 2008, 117, e510-26.	1.6	1,243
4	Socioeconomic Status and Cardiovascular Outcomes. <i>Circulation</i> , 2018, 137, 2166-2178.	1.6	737
5	Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008. <i>Circulation</i> , 2011, 124, 1046-1058.	1.6	519
6	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	1.5	430
7	Management of High Blood Pressure in Blacks. <i>Hypertension</i> , 2010, 56, 780-800.	2.7	398
8	Zika virus pandemicâ€”analysis of Facebook as a social media health information platform. <i>American Journal of Infection Control</i> , 2017, 45, 301-302.	2.3	298
9	Emergence of Nonobstructive Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1918-1933.	2.8	257
10	Hypertension in the United States, 1999 to 2012. <i>Circulation</i> , 2014, 130, 1692-1699.	1.6	176
11	Hypertension Across a Womanâ€™s Life Cycle. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1797-1813.	2.8	159
12	Disparities in hypertension and cardiovascular disease in blacks: The critical role of medication adherence. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1015-1024.	2.0	127
13	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 259-352.	2.3	125
14	Improving Medication Adherence in Cardiometabolic Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 437-451.	2.8	118
15	Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2014, 64, 731-737.	2.7	111
16	Barbershops as Hypertension Detection, Referral, and Follow-Up Centers for Black Men. <i>Hypertension</i> , 2007, 49, 1040-1046.	2.7	106
17	Progression Is Accelerated From Prehypertension to Hypertension in Blacks. <i>Hypertension</i> , 2011, 58, 579-587.	2.7	104
18	Ten things to know about ten cardiovascular disease risk factors. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100149.	3.0	87

#	ARTICLE	IF	CITATIONS
19	Quality and Equitable Health Care Gaps for Women. <i>Journal of the American College of Cardiology</i> , 2017, 70, 373-388.	2.8	86
20	Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis. <i>Journal of Medical Virology</i> , 2020, 92, 2473-2488.	5.0	83
21	The Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Disease Outcomes (credo). <i>Journal of the American College of Cardiology</i> , 2011, 57, 245-252.	2.8	82
22	The Management of Hypertension in African Americans. <i>Critical Pathways in Cardiology</i> , 2007, 6, 67-71.	0.5	79
23	2014 Hypertension Recommendations From the Eighth Joint National Committee Panel Members Raise Concerns for Elderly Black and Female Populations. <i>Journal of the American College of Cardiology</i> , 2014, 64, 394-402.	2.8	79
24	Research Needs to Improve Hypertension Treatment and Control in African Americans. <i>Hypertension</i> , 2016, 68, 1066-1072.	2.7	78
25	Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension. <i>Circulation</i> , 2019, 139, 2098-2109.	1.6	73
26	African-American COVID-19 Mortality. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2746-2748.	2.8	70
27	The Metabolic Syndrome in African Americans: a review. <i>Ethnicity and Disease</i> , 2003, 13, 414-28.	2.3	66
28	Lessons Learned From the Healthy Heart Community Prevention Project in Reaching the African American Population. <i>Journal of Health Care for the Poor and Underserved</i> , 1997, 8, 366-371.	0.8	58
29	Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. <i>Cardiovascular Diabetology</i> , 2016, 15, 38.	6.8	58
30	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100335.	3.0	58
31	Efficacy and Safety of Fibrinolytic, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins. <i>Circulation</i> , 2019, 140, 138-146.	1.6	52
32	Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015, 31, 913-923.	1.9	51
33	Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100250.	3.0	51
34	Women, Hypertension, and the Systolic Blood Pressure Intervention Trial. <i>American Journal of Medicine</i> , 2016, 129, 1030-1036.	1.5	50
35	Community-Based Approaches to Prevention and Management of Hypertension and Cardiovascular Disease. <i>Journal of Clinical Hypertension</i> , 2012, 14, 336-343.	2.0	48
36	Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: The Atherosclerosis Risk in Communities Study. <i>American Heart Journal</i> , 2015, 169, 155-161.e5.	2.7	48

#	ARTICLE	IF	CITATIONS
37	Management of Essential Hypertension. <i>Cardiology Clinics</i> , 2017, 35, 231-246.	2.2	48
38	Hypertension in African Americans: Advances in community outreach and public health approaches. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 40-45.	3.1	48
39	Noninvasive Imaging to Evaluate Women With Stable Ischemic Heart Disease. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 421-435.	5.3	45
40	The Role of Hypertension in Race-Ethnic Disparities in Cardiovascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	2.0	42
41	Update on hypertension in African-Americans. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 33-39.	3.1	42
42	Clinical Use of Pulse Wave Analysis: Proceedings From a Symposium Sponsored by North American Artery. <i>Journal of Clinical Hypertension</i> , 2015, 17, 503-513.	2.0	41
43	Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 249-262.	3.1	41
44	The COVID-19 and Influenza "Twindemic": Barriers to Influenza Vaccination and Potential Acceptance of SARS-CoV2 Vaccination in African Americans. <i>Journal of the National Medical Association</i> , 2020, 112, 681-687.	0.8	38
45	Race, Ethnicity, Hypertension, and Heart Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2460-2470.	2.8	36
46	Cardiorenal Metabolic Syndrome and Cardiometabolic Risks in Minority Populations. <i>CardioRenal Medicine</i> , 2014, 4, 1-11.	1.9	34
47	Working Agenda for Black Mothers. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007643.	2.2	34
48	Management of Women With Acquired Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1799-1812.	2.8	33
49	Race-based therapy for hypertension: possible benefits and potential pitfalls. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1357-1366.	1.5	31
50	2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	29
51	Are SGLT2 Inhibitors New Hypertension Drugs?. <i>Circulation</i> , 2021, 143, 1750-1753.	1.6	29
52	Practical, Evidence-Based Approaches to Nutritional Modifications to Reduce Atherosclerotic Cardiovascular Disease: An American Society For Preventive Cardiology Clinical Practice Statement. <i>American Journal of Preventive Cardiology</i> , 2022, 10, 100323.	3.0	27
53	Hypertension in Minority Populations: New Guidelines and Emerging Concepts. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 145-153.	1.4	26
54	Hypertension in the US Black Population: Risk Factors, Complications, and Potential Impact of Central Aortic Pressure on Effective Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 157-165.	2.6	25

#	ARTICLE	IF	CITATIONS
55	Sociodemographic Determinants of Life's Simple 7: Implications for Achieving Cardiovascular Health and Health Equity Goals. <i>Ethnicity and Disease</i> , 2020, 30, 637-650.	2.3	25
56	Overcoming Barriers to COVID-19 Vaccination in African Americans: The Need for Cultural Humility. <i>American Journal of Public Health</i> , 2021, 111, 586-588.	2.7	23
57	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <sc>SCAI</sc> and <sc>NKF</sc>. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 416-426.	1.7	21
58	Peripheral and Central Blood Pressure Responses of Combination Aliskiren/Hydrochlorothiazide and Amlodipine Monotherapy in African American Patients With Stage 2 Hypertension: The ATLAAS Trial. <i>Journal of Clinical Hypertension</i> , 2011, 13, 366-375.	2.0	20
59	Hypertension in Minority Populations. <i>Journal of Clinical Hypertension</i> , 2006, 8, 365-368.	2.0	18
60	Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002232.	3.9	18
61	PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a). <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 295-308.	2.6	18
62	Heart failure with preserved ejection fraction: Similarities and differences between women and men. <i>International Journal of Cardiology</i> , 2020, 304, 101-108.	1.7	18
63	Understanding the Importance of Race/Ethnicity in the Care of the Hypertensive Patient. <i>Current Hypertension Reports</i> , 2015, 17, 15.	3.5	17
64	Nebivolol in High-Risk, Obese African Americans With Stage 1 Hypertension: Effects on Blood Pressure, Vascular Compliance, and Endothelial Function. <i>Journal of Clinical Hypertension</i> , 2009, 11, 720-725.	2.0	15
65	State-of-the-Art review: Hypertension practice guidelines in the era of COVID-19. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100038.	3.0	15
66	Uncontrolled hypertension in sub-Saharan Africa: Now is the time to address a looming crisis. <i>Journal of Clinical Hypertension</i> , 2020, 22, 2111-2113.	2.0	15
67	Disparate Cardiovascular Disease Rates in African Americans: The Role of Stress Related to Self-Reported Racial Discrimination. <i>Mayo Clinic Proceedings</i> , 2017, 92, 689-692.	3.0	14
68	Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. <i>Journal of the American Heart Association</i> , 2021, 10, e016839.	3.7	14
69	Recognition and Management of Hypertension in Older Persons: Focus on African Americans. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2130-2138.	2.6	13
70	Contemporary and Future Concepts on Hypertension in African Americans: COVID-19 and Beyond. <i>Journal of the National Medical Association</i> , 2020, 112, 315-323.	0.8	13
71	A Review of the Efficacy and Tolerability of Combination Amlodipine/Valsartan in Non-White Patients with Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 301-313.	2.2	11
72	A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk. <i>Current Cardiology Reports</i> , 2015, 17, 38.	2.9	11

#	ARTICLE	IF	CITATIONS
73	Community Outreach to African-Americans: Implementations for Controlling Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 33.	3.5	11
74	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. <i>Journal of Clinical Lipidology</i> , 2019, 13, 586-593.e5.	1.5	11
75	The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 64-73.	3.1	11
76	Will the 2021 USPSTF Hypertension Screening Recommendation Decrease or Worsen Racial/Ethnic Disparities in Blood Pressure Control?. <i>JAMA Network Open</i> , 2021, 4, e213718.	5.9	11
77	Hypertension and cardiovascular disease in the sub-Saharan African context. <i>Annals of Translational Medicine</i> , 2018, 6, 297-297.	1.7	11
78	Current concepts in the management of stable ischemic heart disease and acute coronary syndrome in patients with hemophilia. <i>Annals of Translational Medicine</i> , 2018, 6, 299-299.	1.7	11
79	Uncontrolled Hypertension in Black Men. <i>Circulation</i> , 2019, 139, 20-23.	1.6	8
80	COVID-19 and Katrina: recalcitrant racial disparities. <i>European Heart Journal</i> , 2020, 41, 3390-3393.	2.2	8
81	The role of racial/ethnic factors in global clinical trials. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 829-832.	3.1	7
82	Global perspectives on cardiometabolic risk and cardiovascular disease: from basic science to bedside. <i>Annals of Translational Medicine</i> , 2018, 6, 290-290.	1.7	7
83	Cardiovascular risk reduction in African Americans: Current concepts and controversies. <i>Global Cardiology Science &amp; Practice</i> , 2016, 2016, e201602.	0.4	7
84	Aliskiren-based dual- and triple-combination therapies in high-risk US minority patients with Stage 2 hypertension. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 219-227.	2.3	6
85	Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents. <i>Current Hypertension Reports</i> , 2014, 16, 455.	3.5	6
86	Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2018, 34, 361-367.	1.9	6
87	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2018, 122, 1496-1505.	1.6	6
88	Hypertension 2020 update: A view from the Crescent City and beyond. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 1.	3.1	6
89	Global interventions in hypertension: new and emerging concepts. <i>Current Opinion in Cardiology</i> , 2021, 36, 436-443.	1.8	6
90	Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure. <i>World Journal of Cardiology</i> , 2016, 8, 401.	1.5	6

#	ARTICLE	IF	CITATIONS
91	Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. Hypertension, 2022, 79, 338-348.	2.7	6
92	Are Cardiovascular Benefits in Statin Lipid Effects Dependent on Baseline Lipid Levels?. Current Atherosclerosis Reports, 2011, 13, 64-72.	4.8	5
93	Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease. Cardiovascular Drugs and Therapy, 2015, 29, 563-572.	2.6	5
94	Novel Interventions in Addressing Racial Disparities in Blood Pressure Control. Circulation, 2018, 138, 339-341.	1.6	5
95	Disparities in hypertension and cardiovascular disease in African Americans: Is the answer in the gut microbiota?. International Journal of Cardiology, 2018, 271, 340-342.	1.7	5
96	Racial disparity in atherosclerotic cardiovascular disease in hospitalized patients with diabetes 2005-2015: Potential warning signs for future U.S. public health. American Journal of Preventive Cardiology, 2020, 4, 100095.	3.0	5
97	Improved identification of secondary hypertension: use of a systematic protocol. Annals of Translational Medicine, 2018, 6, 293-293.	1.7	5
98	Fixed-Dose Isosorbide Dinitrate-Hydralazine: Race-Based Cardiovascular Medicine Benefit or Mirage?. Journal of Law, Medicine and Ethics, 2008, 36, 458-463.	0.9	4
99	Food Deserts. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	4
100	Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists-what will REWIND add?. Annals of Translational Medicine, 2017, 5, 476-476.	1.7	4
101	Primordial Prevention of Cardiovascular Disease in Childhood. Journal of the American College of Cardiology, 2019, 73, 2022-2024.	2.8	4
102	Understanding African American COVID-19 Severity and Mortality: Is Obesity the Key?. Obesity, 2020, 28, 1793-1794.	3.0	4
103	Disparities in the COVID-19 pandemic: A clarion call for preventive cardiology. American Journal of Preventive Cardiology, 2021, 8, 100283.	3.0	4
104	A Compendium of Antihypertensive Therapy. Journal of Clinical Hypertension, 2011, 13, 636-638.	2.0	3
105	Improving Approaches to Hypertension Treatment in African Americans: Lessons Learned From the Jackson Heart Study. Journal of Clinical Hypertension, 2013, 15, 362-364.	2.0	3
106	Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry research-practice-project from the diabetes collaborative registry. Diabetes, Obesity and Metabolism, 2019, 21, 393-396.	4.4	2
107	Heart Failure Hospitalizations and Risk Factors among the Multi-Ethnic Population from a Middle Income Country: The Suriname Heart Failure Studies. Journal of the National Medical Association, 2021, 113, 177-186.	0.8	2
108	Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy. CardioRenal Medicine, 2012, 2, 256-267.	1.9	1



#	ARTICLE	IF	CITATIONS
109	Improved Understanding and Innovative Approaches for an Aging Dilemma: Resistant Hypertension in Women with Existing Vascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 450-458.	2.0	1
110	Race/Ethnicity in Atrial Fibrillation Stroke: Epidemiology and Pharmacotherapy. <i>Journal of the National Medical Association</i> , 2015, 107, 59-67.	0.8	1
111	Revealing Masked Hypertension in People of African Ancestry: We Need to Do Better. <i>Journal of Clinical Hypertension</i> , 2016, 18, 393-395.	2.0	1
112	Opportunities for improving cardiovascular health outcomes in adults younger than 65 years with guideline-recommended statin therapy. <i>Journal of Clinical Hypertension</i> , 2017, 19, 850-860.	2.0	1
113	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. <i>Journal of Clinical Lipidology</i> , 2019, 13, 735-743.	1.5	1
114	Image-Guided Intensity-Modulated Radiation Therapy for IgG4-Related Ophthalmic Disease. <i>Case Reports in Ophthalmological Medicine</i> , 2020, 2020, 1-4.	0.5	1
115	COVID-19 Mitigation: Individual Freedom Should Not Impede Public Health. <i>American Journal of Public Health</i> , 2021, 111, 592-593.	2.7	1
116	Response to the letter to the editor by Silverman-Lloyd et al. entitled: "Race is not a risk factor: Reframing discourse on racial health inequities in CVD prevention". <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100188.	3.0	1
117	Cardiovascular Disparities Up South: The Intersection of Geography, Social Determinants, and Race. <i>Mayo Clinic Proceedings</i> , 2022, 97, 7-9.	3.0	1
118	Obesity and hypertension: It's about more than the numbers. <i>Obesity</i> , 2013, 21, 657-658.	3.0	0
119	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3009-3010.	2.8	0
120	Nocturnal Hypertension and Nondipping Blood Pressure: Nature or Nurture?. <i>American Journal of Hypertension</i> , 2019, 32, 720-722.	2.0	0
121	Improved pathways to hypertension control and elimination of disparities: Are we there yet?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 499-501.	2.0	0
122	Cardiovascular Disease in Minorities: Unique Considerations: Hypertension in African and Hispanic Americans. <i>Contemporary Cardiology</i> , 2021, , 159-166.	0.1	0
123	Overview and Perspectives: Cardiovascular Disease in Racial/Ethnic Minorities in the Era of COVID-19. <i>Contemporary Cardiology</i> , 2021, , 1-11.	0.1	0
124	Dietary Approaches to Hypertension: Dietary Sodium and the DASH Diet for Cardiovascular Health. <i>Contemporary Cardiology</i> , 2021, , 61-72.	0.1	0
125	Physical Activity. <i>Mayo Clinic Proceedings</i> , 2021, 96, 844-846.	3.0	0
126	HDL-C for Atherosclerotic Risk Assessment: Is it Time to Move on?. <i>American Journal of the Medical Sciences</i> , 2021, 362, 433-434.	1.1	0



#	ARTICLE	IF	CITATIONS
127	Racial/Ethnic Considerations in the Prevention of Cardiovascular Disease. Contemporary Cardiology, 2021, , 463-487.	0.1	0
128	Achieving treatment goals in low-risk, asymptomatic patients. Journal of the American Osteopathic Association, The, 2010, 110, S7-13.	1.7	0